<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Annals of the Russian academy of medical sciences</journal-id><journal-title-group><journal-title xml:lang="en">Annals of the Russian academy of medical sciences</journal-title><trans-title-group xml:lang="ru"><trans-title>Вестник Российской академии медицинских наук</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0869-6047</issn><issn publication-format="electronic">2414-3545</issn><publisher><publisher-name xml:lang="en">"Paediatrician" Publishers LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">2094</article-id><article-id pub-id-type="doi">10.15690/vramn2094</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>INFECTIOUS DISEASES: CURRENT ISSUES</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>АКТУАЛЬНЫЕ ВОПРОСЫ ИНФЕКЦИОННЫХ БОЛЕЗНЕЙ</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Von Willebrand Factor and Myeloperoxidase as Laboratory Predictive Markers of In-Hospital Survival in Severe COVID-19 Patients</article-title><trans-title-group xml:lang="ru"><trans-title>Фактор фон Виллебранда и миелопероксидаза как лабораторные предикторы выживаемости при тяжелом течении COVID-19</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7415-4633</contrib-id><contrib-id contrib-id-type="scopus">6602363216</contrib-id><contrib-id contrib-id-type="researcherid">M-5660-2016</contrib-id><contrib-id contrib-id-type="spin">7538-2966</contrib-id><name-alternatives><name xml:lang="en"><surname>Makatsariya</surname><given-names>Alexander D.</given-names></name><name xml:lang="ru"><surname>Макацария</surname><given-names>Александр Давидович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, PhD, Professor, Academician of the RAS</p></bio><bio xml:lang="ru"><p>д.м.н., профессор, академик РАН</p></bio><email>gemostasis@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0725-9686</contrib-id><contrib-id contrib-id-type="scopus">57194547147</contrib-id><contrib-id contrib-id-type="researcherid">F-8384-2017</contrib-id><contrib-id contrib-id-type="spin">8225-4976</contrib-id><name-alternatives><name xml:lang="en"><surname>Khizroeva</surname><given-names>Jamilya Kh.</given-names></name><name xml:lang="ru"><surname>Хизроева</surname><given-names>Джамиля Хизриевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, PhD, Professor</p></bio><bio xml:lang="ru"><p>д.м.н., профессор</p></bio><email>jamatotu@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2802-4090</contrib-id><contrib-id contrib-id-type="spin">5950-3930</contrib-id><name-alternatives><name xml:lang="en"><surname>Schoenfeld</surname><given-names>Yehuda</given-names></name><name xml:lang="ru"><surname>Шенфельд</surname><given-names>Иегуда</given-names></name></name-alternatives><address><country country="IL">Israel</country></address><bio xml:lang="en"><p>MD, Professor</p></bio><bio xml:lang="ru"><p>доктор медицины, профессор</p></bio><email>yehuda.shoenfeld@sheba.health.gov.il</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3628-0804</contrib-id><contrib-id contrib-id-type="spin">1463-0065</contrib-id><name-alternatives><name xml:lang="en"><surname>Tretyakova</surname><given-names>Maria V.</given-names></name><name xml:lang="ru"><surname>Третьякова</surname><given-names>Мария Владимировна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, PhD, Assistant Professor</p></bio><bio xml:lang="ru"><p>к.м.н., доцент</p></bio><email>tretyakova777@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7441-2778</contrib-id><contrib-id contrib-id-type="spin">7423-8944</contrib-id><name-alternatives><name xml:lang="en"><surname>Slukhanchuk</surname><given-names>Ekaterina V.</given-names></name><name xml:lang="ru"><surname>Слуханчук</surname><given-names>Екатерина Викторовна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, PhD, Assistant Professor</p></bio><bio xml:lang="ru"><p>к.м.н., доцент</p></bio><email>beloborodova@rambler.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9783-1796</contrib-id><contrib-id contrib-id-type="spin">5388-7701</contrib-id><name-alternatives><name xml:lang="en"><surname>Shkoda</surname><given-names>Andrei S.</given-names></name><name xml:lang="ru"><surname>Шкода</surname><given-names>Андрей Сергеевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, PhD, Professor</p></bio><bio xml:lang="ru"><p>д.м.н., профессор</p></bio><email>67gkb@mail.ru</email><xref ref-type="aff" rid="aff4"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1339-4155</contrib-id><contrib-id contrib-id-type="scopus">7006391091</contrib-id><contrib-id contrib-id-type="spin">5465-1880</contrib-id><name-alternatives><name xml:lang="en"><surname>Pankratyeva</surname><given-names>Lyudmila L.</given-names></name><name xml:lang="ru"><surname>Панкратьева</surname><given-names>Людмила Леонидовна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, PhD, Professor</p></bio><bio xml:lang="ru"><p>д.м.н., профессор</p></bio><email>liudmila.pankratyeva@gmail.com</email><xref ref-type="aff" rid="aff5"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1236-398X</contrib-id><contrib-id contrib-id-type="spin">3639-0239</contrib-id><name-alternatives><name xml:lang="en"><surname>Petrovsky</surname><given-names>Mikhail I.</given-names></name><name xml:lang="ru"><surname>Петровский</surname><given-names>Михаил Игоревич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>PhD in Physical and Mathematical Sciences</p></bio><bio xml:lang="ru"><p>к.ф.-м.н.</p></bio><email>michael@cs.msu.su</email><xref ref-type="aff" rid="aff6"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9837-585X</contrib-id><contrib-id contrib-id-type="spin">6924-0704</contrib-id><name-alternatives><name xml:lang="en"><surname>Mashechkin</surname><given-names>Igor V.</given-names></name><name xml:lang="ru"><surname>Машечкин</surname><given-names>Игорь Валерьевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>PhD in Physical and Mathematical Sciences</p></bio><bio xml:lang="ru"><p>д.ф.-м.н.</p></bio><email>mash@cs.msu.su</email><xref ref-type="aff" rid="aff6"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3367-9844</contrib-id><contrib-id contrib-id-type="scopus">6701744871</contrib-id><contrib-id contrib-id-type="researcherid">E-8906-2017</contrib-id><contrib-id contrib-id-type="spin">9779-8290</contrib-id><name-alternatives><name xml:lang="en"><surname>Blinov</surname><given-names>Dmitry V.</given-names></name><name xml:lang="ru"><surname>Блинов</surname><given-names>Дмитрий Владиславович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, PhD</p></bio><bio xml:lang="ru"><p>к.м.н.</p></bio><email>blinov2010@googlemail.com</email><xref ref-type="aff" rid="aff7"/><xref ref-type="aff" rid="aff8"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9899-9910</contrib-id><contrib-id contrib-id-type="scopus">7005114260</contrib-id><name-alternatives><name xml:lang="en"><surname>Gris</surname><given-names>Jean-Christophe R.</given-names></name><name xml:lang="ru"><surname>Грис</surname><given-names>Жан-Кристоф Раймонд</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, PhD, Professor</p></bio><bio xml:lang="ru"><p>доктор медицины, д.м.н., профессор</p></bio><email>jean.christophe.gris@chu-nimes.fr</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff9"/><xref ref-type="aff" rid="aff10"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8404-1042</contrib-id><contrib-id contrib-id-type="spin">5930-0859</contrib-id><name-alternatives><name xml:lang="en"><surname>Bitsadze</surname><given-names>Victoria O.</given-names></name><name xml:lang="ru"><surname>Бицадзе</surname><given-names>Виктория Омаровна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, PhD, Professor</p></bio><bio xml:lang="ru"><p>д.м.н., профессор</p></bio><email>vikabits@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">I.M. Sechenov First Moscow State Medical University (Sechenov University)</institution></aff><aff><institution xml:lang="ru">Первый Московский государственный университет имени И.М. Сеченова (Сеченовский Университет)</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Ariel University</institution></aff><aff><institution xml:lang="ru">Университет Ариэль</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">Petrovsky National Research Center of Surgery</institution></aff><aff><institution xml:lang="ru">Российский научный центр хирургии имени академика Б.В. Петровского</institution></aff></aff-alternatives><aff-alternatives id="aff4"><aff><institution xml:lang="en">L.A. Vorokhobov City Clinical Hospital No. 67</institution></aff><aff><institution xml:lang="ru">Городская клиническая больница № 67 имени Л.А. Ворохобова</institution></aff></aff-alternatives><aff-alternatives id="aff5"><aff><institution xml:lang="en">Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology</institution></aff><aff><institution xml:lang="ru">Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии имени Дмитрия Рогачева</institution></aff></aff-alternatives><aff-alternatives id="aff6"><aff><institution xml:lang="en">Lomonosov Moscow State University</institution></aff><aff><institution xml:lang="ru">Московский государственный университет имени М.В. Ломоносова</institution></aff></aff-alternatives><aff-alternatives id="aff7"><aff><institution xml:lang="en">Institute for Social and Preventive Medicine</institution></aff><aff><institution xml:lang="ru">Институт превентивной и социальной медицины</institution></aff></aff-alternatives><aff-alternatives id="aff8"><aff><institution xml:lang="en">Lapino Clinical Hospital, MD Medical Group</institution></aff><aff><institution xml:lang="ru">Клинический госпиталь «Лапино» группы компаний «Мать и Дитя»</institution></aff></aff-alternatives><aff-alternatives id="aff9"><aff><institution xml:lang="en">University Hospital of Nîmes</institution></aff><aff><institution xml:lang="ru">Университетская клиника Нима</institution></aff></aff-alternatives><aff-alternatives id="aff10"><aff><institution xml:lang="en">University of Montpellier</institution></aff><aff><institution xml:lang="ru">Университет Монпелье</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2022-07-31" publication-format="electronic"><day>31</day><month>07</month><year>2022</year></pub-date><volume>77</volume><issue>3</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>189</fpage><lpage>198</lpage><history><date date-type="received" iso-8601-date="2022-05-20"><day>20</day><month>05</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2022-06-21"><day>21</day><month>06</month><year>2022</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2022, "Paediatrician" Publishers LLC</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2022, Издательство "Педиатръ"</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="en">"Paediatrician" Publishers LLC</copyright-holder><copyright-holder xml:lang="ru">Издательство "Педиатръ"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/" start_date="2023-07-31"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://vestnikramn.spr-journal.ru/jour/about/submissions</ali:license_ref></license></permissions><self-uri xlink:href="https://vestnikramn.spr-journal.ru/jour/article/view/2094">https://vestnikramn.spr-journal.ru/jour/article/view/2094</self-uri><abstract xml:lang="en"><p><bold><italic>Background. </italic></bold><italic>The severe acute respiratory syndrome of the SARS-CoV-2 virus-mediated coronavirus disease 2019 (COVID-19) highlighted the central role of immunothrombosis. Severe endothelial damage with the release of unusually large multimers of von Willebrand factor (vWF) and subsequent consumption of ADAMTS-13 is described during severe COVID-19. The activation of innate immune cells among which neutrophils contribute to the formation of extracellular neutrophil traps (NETs) and to the release of myeloperoxidase (MPO) potentially contributing to the spread of inflammation and microvascular thrombosis. <bold>Objective — </bold>to evaluate the ability of vWF, ADAMTS-13 and MPO to predict in-hospital mortality in severe COVID-19 patients needing mechanical ventilation. <bold>Methods.</bold> We performed a one-center observational study of 79 severe COVID-19 patients entering intensive care unit for mechanical ventilation, examining vWF, ADAMTS-13 and MPO among other potential predictors for in-hospital death. <bold>Results. </bold>After multivariate analysis, vWF antigen (vWF:Ag) and MPO antigen (MPO:Ag) were finally the single two parameters which increasing values were independently associated with non-survival; vWF:Ag (U/dL): adjusted OR 3.360, 95% CI 1.562–7.228, p = 0.0019; MPO:Ag (ng/ml): adjusted OR 1.062, 95% CI 1.024–1.101, p = 0.0011. From these results a simplified mortality score was derived and patients categorized as having a score value higher or lower that the median value of the score: a high score value was associated with a lower cumulative survival rate (p &lt; 0.0001), 50% of the cases being dead at day 13 post-hospital admission. <bold>Conclusions. </bold>In severe COVID-19 necessitating mechanical ventilation<bold>, </bold>increasing values of MPO activity and of vWF antigen tested at admission are associated with poor survival.</italic></p></abstract><trans-abstract xml:lang="ru"><p><bold><italic>Обоснование.</italic></bold><italic> Тяжелый острый респираторный синдром, запускаемый вирусом SARS-CoV-2, обозначил центральную роль в патогенезе иммунотромбоза. При тяжелом течении COVID-19 описано массивное повреждение эндотелия с высвобождением большого количества мультимеров фактора фон Виллебранда (vWF) и последующим потреблением ADAMTS-13. Активация клеток врожденного иммунитета, в том числе нейтрофилов, приводит к образованию нейтрофильных внеклеточных ловушек (</italic><italic>NETs</italic><italic>) и высвобождению миелопероксидазы (МПО), что, в свою очередь, способствует распространению процессов воспаления и тромбоза в микрососудистом русле. <bold>Цель</bold> — оценить прогностическую ценность концентрации vWF, ADAMTS-13 и MПO в отношении внутрибольничной смертности у пациентов с тяжелой формой COVID-19, нуждающихся в искусственной вентиляции легких (ИВЛ). <bold>Методы.</bold> Проведено одноцентровое наблюдательное исследование с участием 79 пациентов с тяжелым течением COVID-19, находившихся в отделении интенсивной терапии на ИВЛ. У всех пациентов определялись концентрации vWF, ADAMTS-13 и MПO в сыворотке крови, а также другие показатели — потенциальные предикторы внутрибольничной смертности. <bold>Результаты.</bold> Путем проведения многофакторного анализа было показано, что увеличение концентрации таких маркеров, как антиген vWF (vWF:Aг) и MПO человека (MПO:Aг), достоверно и независимо связано с высокой вероятностью смертности; vWF:Aг (ЕД/дл): скорректированное ОШ 3,360; 95%-й ДИ 1,562–7,228; р = 0,0019; MПO:Aг (нг/мл): скорректированное ОШ 1,062; 95%-й ДИ 1,024–1,101; р = 0,0011. На основании этих результатов был получен упрощенный показатель смертности, и пациенты были классифицированы как имеющие значения данного показателя выше или ниже медианного: высокое значение показателя было связано с более низкой кумулятивной выживаемостью (p &lt; 0,0001), в 50% случаев смерть наступала на 13-е сут госпитализации. <bold>Выводы.</bold> При тяжелом течении COV</italic><italic>I</italic><italic>D-19, требующем ИВЛ, повышенные концентрации МПО и vWF на момент поступления коррелируют с плохой выживаемостью.</italic></p></trans-abstract><kwd-group xml:lang="en"><kwd>COVID-19</kwd><kwd>ADAMTS-13</kwd><kwd>von Willebrand Factor</kwd><kwd>myeloperoxydase</kwd><kwd>survival</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>COVID-19</kwd><kwd>ADAMTS-13</kwd><kwd>фактор фон Виллебранда</kwd><kwd>миелопероксидаза</kwd><kwd>выживаемость</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution xml:lang="ru">Российский фонд фундаментальных исследований (РФФИ)</institution></institution-wrap></funding-source><award-id>20-04-60274</award-id></award-group></funding-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Bonaventura A, Vecchié A, Dagna L, et al. Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19. Nat Rev Immunol. 2021;21:319–329. doi: https://doi.org/10.1038/s41577-021-00536-9</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Landau N, Shoenfeld Y, Negru L, et al. Exploring the pathways of inflammation and coagulopathy in COVID-19: A narrative tour into a viral rabbit hole. Int Rev Immunol. 2021;22:1–9. doi: https://doi.org/10.1080/08830185.2021.1993211</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Макацария А.Д., Слуханчук Е.В., Бицадзе В.О., и др. Тромботический шторм, нарушения гемостаза и тромбовоспаление в условиях COVID-19 // Акушерство, гинекология и репродукция. — 2021. — Т. 15. — № 5. — С. 499–514. [Makatsariya AD, Slukhanchuk EV, Bitsadze VO, et al. Thrombotic storm, hemostasis disorders and thromboinflammation in COVID-19. Obstetrics, Gynecology and Reproduction. 2021;15(5):499–514. (In Russ.)] doi: https://doi.org/10.17749/2313-7347/ob.gyn.rep.2021.247</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Iba T, Levy JH, Levi M, et al. Coagulopathy in COVID-19. J Thromb Haemost. 2020;18(9):2103–2109. doi: https://doi.org/10.1111/jth.14975</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Макацария А.Д., Григорьева К.Н., Мингалимов М.А., и др. Коронавирусная инфекция (COVID-19) и синдром диссеминированного внутрисосудистого свертывания // Акушерство, гинекология и репродукция. — 2020. — Т. 14. — № 2. — С. 123–131. [Makatsariya AD, Grigoreva KN ingalimov M.A., et al. Coronavirus disease (COVID-19) and disseminated intravascular coagulation syndrome. Obstetrics, Gynecology and Reproduction. 2020;14(2):123–131. (In Russ.)] doi: https://doi.org/10.17749/2313-7347.132</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Бицадзе В.О., Слуханчук Е.В., Хизроева Д.Х., и др. Внеклеточные ловушки нейтрофилов (NETs) в патогенезе тромбоза и тромбовоспалительных заболеваний // Вестник РАМН. — 2021. — Т. 76. — № 1. — C. 75–85. [Bitsadze VO, Slukhanchuk EV, Khizroeva JKh, et al. Extracellular Neutrophil Traps (NETs) in the Pathogenesis of Thrombosis and Thromboinflammation. Annals of the Russian Academy of Medical Sciences. 2021;76(1):75–85. (In Russ.)] doi: https://doi.org/10.15690/vramn1395</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Favaloro EJ, Henry BM, Lippi G. Increased VWF and Decreased ADAMTS-13 in COVID-19: Creating a Milieu for (Micro)Thrombosis. Semin Thromb Hemost. 2021;47(4):400–418. doi: https://doi.org/10.1055/s-0041-1727282</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Fujimura Y., Holland LZ. COVID-19 microthrombosis: unusually large VWF multimers are a platform for activation of the alternative complement pathway under cytokine storm. Int J Hematol. 2022;115(4):457–469. doi: https://doi.org/10.1007/s12185-022-03324-w</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Hafez W, Ziade MA, Arya A, et al. Reduced ADAMTS-13 Activity in Correlation with Pathophysiology, Severity, and Outcome of COVID-19: A Retrospective Observational Study. Int J Infect Dis. 2022;117:334–344. doi: https://doi.org/10.1016/j.ijid.2022.02.019</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Nguyen TC, Liu A, Liu L, et al. Acquired ADAMTS-13 deficiency in pediatric patients with severe sepsis. Haematologica. 2007;92(1):121–124. doi: https://doi.org/10.3324/haematol.10262</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Ruf W, Ruggeri Z. Neutrophils release brakes of coagulation. Nat Med. 2010;16(8):851–852. doi: https://doi.org/10.1038/nm0810-851</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Макацария А.Д., Слуханчук Е.В., Бицадзе В.О., и др. Внеклеточные ловушки нейтрофилов участие в процессах воспаления и дизрегуляции гемостаза, в том числе у пациентов с COVID-19 и тяжелой акушерской патологией // Акушерство, гинекология и репродукция. —2021. — Т. 15. — № 4. — С. 335–350. [Makatsariya AD, Slukhanchuk EV, Bitsadze VO, et al. Neutrophil extracellular traps: a role in inflammation and dysregulated hemostasis as well as in patients with COVID-19 and severe obstetric pathology. Obstetrics, Gynecology and Reproduction. 2021;15(4):335–350. (In Russ.)] doi: https://doi.org/10.17749/2313-7347/ob.gyn.rep.2021.238</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Pramitasuri TI, Laksmidewi AAAP, Putra IBK, et al. Neutrophil Extracellular Traps in Coronavirus Disease-19-Associated Ischemic Stroke: A Novel Avenue in Neuroscience. Exp Neurobiol. 2021;30(1):1–12. doi: https://doi.org/10.5607/en20048</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Loria V, Dato I, Graziani F, et al. Myeloperoxidase: a new biomarker of inflammation in ischemic heart disease and acute coronary syndromes. Mediators Inflamm. 2008;2008:135625. doi: https://doi.org/10.1155/2008/135625</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Lissalde-Lavigne G, Combescure C, Muller L, et al. Simple coagulation tests improve survival prediction in patients with septic shock. J Thromb Haemost. 2008;6(4):645–653. doi: https://doi.org/10.1111/j.1538-7836.2008.02895</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Zuo Y, Yalavarthi S, Shi H, et al. Neutrophil extracellular traps (NETs) as markers of disease severity in COVID-19. medRxiv. 2020;2020.04.09.20059626. doi: https://doi.org/10.1101/2020.04.09.20059626</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Sweeney JM, Barouqa M, Krause GJ, et al. Evidence for secondary thrombotic microangiopathy in COVID-19. medRxiv. 2020;2020.10.20.20215608. doi: https://doi.org/10.1101/2020.10.20.20215608</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Henry BM, Benoit SW, de Oliveira MHS, et al. ADAMTS-13 activity to von Willebrand factor antigen ratio predicts acute kidney injury in patients with COVID-19: Evidence of SARS-CoV-2 induced secondary thrombotic microangiopathy. Int J Lab Hematol. 2021;43(Suppl1):129–136. doi: https://doi.org/10.1111/ijlh.13415</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Rauch A, Labreuche J, Lassalle F, et al. Coagulation biomarkers are independent predictors of increased oxygen requirements in COVID-19. J Thromb Haemost. 2020;18(11):2942–2953. doi: https://doi.org/10.1111/jth.15067</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Ward SE, Curley GF, Lavin M, et al. Irish COVID-19 Vasculopathy Study (ICVS) Investigators. Von Willebrand factor propeptide in severe coronavirus disease 2019 (COVID-19): evidence of acute and sustained endothelial cell activation. Br J Haematol. 2021;192(4):714–719. doi: https://doi.org/10.1111/bjh.17273</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Vassiliou AG, Keskinidou C, Jahaj E, et al. ICU admission levels of endothelial biomarkers as predictors of mortality in critically ill COVID-19 patients. Cells. 2021;10(1):186. doi: https://doi.org/10.3390/cells10010186</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Tiscia GL, Favuzzi G, De Laurenzo A, et al. CSS COVID-19 Group. Reduction of ADAMTS-13 levels predicts mortality in SARS-CoV-2 patients. TH Open. 2020;4(3):e203–e206. doi: https://doi.org/10.1055/s-0040-1716379</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Pascreau T, Zia-Chahabi S, Zuber B, et al. ADAMTS 13 deficiency is associated with abnormal distribution of von Willebrand factor multimers in patients with COVID-19. Thromb Res. 2021;204:138–140. doi: https://doi.org/10.1016/j.thromres.2021.02.008</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>De Jongh R, Ninivaggi M, Mesotten D, et al. Vascular activation is a strong predictor of mortality in coronavirus disease 2019 patients on the ICU. Blood Coagul Fibrinolysis. 2021;32(4):290–293. doi: https://doi.org/10.1097/MBC.0000000000001007</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Ryabkova VA, Churilov LP, Shoenfeld Y. Influenza infection, SARS, MERS and COVID-19: Cytokine storm — The common denominator and the lessons to be learned. Clin Immunol. 2021;223:108652. doi: https://doi.org/10.1016/j.clim.2020.108652</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Ryabkova VA, Churilov LP, Shoenfeld Y. Influenza infection, SARS, MERS and COVID-19: Cytokine storm — The common denominator and the lessons to be learned. Clin Immunol. 2021;223:108652. doi: https://doi.org/10.1016/j.clim.2020.108652</mixed-citation></ref></ref-list></back></article>
